Glen Eagle Advisors LLC Acquires 1,103 Shares of Novo Nordisk A/S (NYSE:NVO)

Glen Eagle Advisors LLC lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 10.4% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,728 shares of the company’s stock after buying an additional 1,103 shares during the period. Glen Eagle Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,396,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. International Assets Investment Management LLC lifted its stake in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC lifted its stake in shares of Novo Nordisk A/S by 257,816.0% in the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after acquiring an additional 1,593,303 shares during the last quarter. Mediolanum International Funds Ltd acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $98,765,000. Marshall Wace LLP grew its position in Novo Nordisk A/S by 34,472.1% during the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after acquiring an additional 689,441 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in Novo Nordisk A/S in the 3rd quarter worth about $42,017,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $110.78 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15. The company has a 50 day simple moving average of $111.51 and a two-hundred day simple moving average of $127.33. The company has a market capitalization of $497.13 billion, a PE ratio of 35.85, a P/E/G ratio of 1.38 and a beta of 0.40.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Buy” and an average target price of $150.40.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.